Use
of tumour necrosis factor (TNF) binders for remedy for psoriasis is linked to a
substantially decreased risk of myocardial infarction (MI) in comparison with
other forms of therapy, based on a report published in Archives of Dermatology.
“The effect of systemic therapy for psoriasis
on cardiovascular disease is largely unusual,” the authors wrote as
background data in the research study.
Dr
Jashin J Wu of the Kaiser Permanente Los Angeles Medical Center, and
professionals, performed a retrospective study that included affected
individuals with a minimum of three ICD-9-CM codes for psoriasis or psoriatic
arthritis, without ever antecedent MI, between January 2004 and November 2010.
Of
the 8,845 affected individuals found in the study, 5,075 (57.4 per cent) were
not treated with any systemic therapy or phototherapy (topical treatment
group), 1,673 (18.9 %) obtained a TNF inhibitor for about a couple of
consecutive months (TNF therapy group) and 2,097 (23.7 %) were handled along
with oral systemic agents or phototherapy (oral/phototherapy therapy group).
After
modifying for other MI factors, affected individuals in the TNF inhibitor
treatment group of individuals and the oral/phototherapy therapy group
experienced a substantially lower risk of MI (50 % and 46 %, respectively)
compared with affected individuals in the topical therapy group.
Dissimilarities in risk amongst the TNF inhibitor group and oral/phototherapy
group didn't reach statistical significance.
No comments:
Post a Comment